Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

REDA Gianluigi CASSIN Ramona DOVRTĚLOVÁ Gabriela MATTEO Cristina GIANNOTTA Juri D'INCALCI Maurizio CORTELEZZI Agostino ZUCCHETTI Massimo

Year of publication 2019
Type Article in Periodical
Magazine / Source Haematologica
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
Doi http://dx.doi.org/10.3324/haematol.2018.213157
Keywords CNS involvement; Chronic Lymphocytic Leukemia; venetoclax
Description Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.